27Jun 2022
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

Two randomized phase III clinical trials targeting unresectable gastric and gastro-oesophagal junction carcinomas validate this observation. Thus, oxaliplatin-based chemotherapy favourably interacted with nivolumab, yielding an improved outcome. In contrast, the outcome of cisplatin-based chemotherapy failed to be improved by concomitant treatment with pembrolizumab. These clinical findings underscore the importance of choosing appropriate ICD-inducing cytotoxicants for developing chemoimmunotherapeutic regimens.

  • #oncology

Like

Save

Share